05/17/2024 4:15 PM | Iovance Biotherapeutics (Filer)
| Form DEFA14A | |
05/01/2024 4:05 PM | Iovance Biotherapeutics (Filer)
| Form ARS | |
04/29/2024 4:06 PM | Iovance Biotherapeutics (Filer)
| Form DEF 14A | |
04/29/2024 4:07 PM | Iovance Biotherapeutics (Filer)
| Form DEFA14A | |
04/17/2024 6:07 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/17/2024 6:07 PM | GRAF FINCKENSTEIN FRIEDRICH (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/17/2024 6:08 PM | Iovance Biotherapeutics (Issuer) Vogt Frederick G (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
03/29/2024 4:00 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/06/2024 5:19 PM | Iovance Biotherapeutics (Issuer) Vogt Frederick G (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2024 5:20 PM | GRAF FINCKENSTEIN FRIEDRICH (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2024 5:17 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2024 4:58 PM | Iovance Biotherapeutics (Issuer) YARNO WENDY L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2024 4:50 PM | Countouriotis Athena (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2024 4:51 PM | Bellemin Jean-Marc (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2024 4:52 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2024 7:00 AM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/01/2024 6:09 PM | Iovance Biotherapeutics (Subject) PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G | |
02/29/2024 6:30 AM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/28/2024 3:05 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/21/2024 3:44 PM | Iovance Biotherapeutics (Filer)
| Form 424B5 | |
02/20/2024 6:52 PM | Iovance Biotherapeutics (Issuer) MCPEAK MERRILL A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2024 4:23 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/20/2024 5:03 AM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/14/2024 5:16 AM | Iovance Biotherapeutics (Subject) Point72 Asset Management, L.P. (Filed by)
| Form SC 13G/A | |
02/09/2024 4:40 PM | Iovance Biotherapeutics (Subject) MHR FUND MANAGEMENT LLC (Filed by)
| Form SC 13G/A | |
01/25/2024 9:49 AM | Iovance Biotherapeutics (Subject) STATE STREET CORP (Filed by)
| Form SC 13G/A | |
01/18/2024 5:07 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/18/2024 5:09 PM | GRAF FINCKENSTEIN FRIEDRICH (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/18/2024 5:09 PM | Iovance Biotherapeutics (Issuer) Vogt Frederick G (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2024 4:03 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/27/2023 4:00 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/07/2023 4:15 PM | Iovance Biotherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/27/2023 3:24 PM | Iovance Biotherapeutics (Subject) Quogue Capital LLC (Filed by)
| Form SC 13D/A | |
10/18/2023 7:03 PM | GRAF FINCKENSTEIN FRIEDRICH (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/18/2023 7:04 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/18/2023 7:05 PM | Iovance Biotherapeutics (Issuer) Vogt Frederick G (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2023 3:30 PM | Iovance Biotherapeutics (Issuer) MCPEAK MERRILL A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/15/2023 5:12 PM | Iovance Biotherapeutics (Issuer) Rothbaum Wayne P. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/15/2023 7:17 AM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/18/2023 4:16 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2023 4:15 PM | Iovance Biotherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
Biden Nomination CANCELED? (Ad) The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.”
Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. |
07/17/2023 5:21 PM | BILINSKY IGOR (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2023 5:22 PM | GRAF FINCKENSTEIN FRIEDRICH (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2023 5:22 PM | Iovance Biotherapeutics (Issuer) Vogt Frederick G (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/13/2023 3:31 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/11/2023 4:08 PM | Iovance Biotherapeutics (Filer)
| Form 424B5 | |
07/11/2023 3:55 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/10/2023 4:27 PM | Iovance Biotherapeutics (Filer)
| Form 424B5 | |
07/10/2023 3:40 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/10/2023 7:53 AM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/16/2023 3:51 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/16/2023 3:39 PM | Iovance Biotherapeutics (Filer)
| Form 424B5 | |
06/16/2023 3:11 PM | Iovance Biotherapeutics (Filer)
| Form S-3ASR | |
06/08/2023 5:20 PM | Iovance Biotherapeutics (Issuer) YARNO WENDY L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/08/2023 5:20 PM | Dukes Iain D. (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/08/2023 5:21 PM | Iovance Biotherapeutics (Issuer) WEISER MICHAEL (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/08/2023 5:21 PM | Iovance Biotherapeutics (Issuer) Maynard Ryan D (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/08/2023 5:21 PM | Iovance Biotherapeutics (Issuer) MCPEAK MERRILL A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/08/2023 5:22 PM | Countouriotis Athena (Reporting) Iovance Biotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/06/2023 4:17 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/02/2023 3:30 PM | Iovance Biotherapeutics (Filer)
| Form 8-K/A | |
05/26/2023 7:38 PM | Iovance Biotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |